A imaging study demonstrating the use of ImmunoPET technology to image T cell infiltration of skeletal muscle in patients with inclusion body myositis (IBM)
Latest Information Update: 08 Jul 2021
Price :
$35 *
At a glance
- Drugs Crefmirlimab (Primary)
- Indications Inclusion body myositis
- Focus Diagnostic use
- 08 Jul 2021 New trial record
- 30 Jun 2021 According to an Abcuro media release, company and ImaginAb shared initial results of this study.
- 30 Jun 2021 According to an Abcuro media release, this studywas led by Colin Quinn, M.D., Assistant Professor of Clinical Neurology and Director of Neuromuscular Clinical Trials at the University of Pennsylvania.